Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant C1 esterase inhibitor
- Development stage
- Preclinical
- Lead developer
- CSL
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
The recombinant C1 esterase inhibitor is a glyco-optimized protein developed by CSL Limited and CEVEC using CEVEC's proprietary CAP(R)Go technology platform. This drug is designed to improve the half-life and provide a more convenient application for patients. Its primary mechanism involves replacing or supplementing the activity of endogenous C1 esterase inhibitor, thereby regulating the complement and contact systems. It is being developed for the treatment of Hereditary Angioedema (HAE) and other potential indications.
- Other names
- C1-INHC-1-INHC 1-INH
02
Targets
FXIIa (Coagulation Factor XIIa)C1R (Complement component 1r subcomponent)Factor XIaMASP1 (MASP-1)MASP2 (Mannan-binding lectin-associated serine protease 2)KLKB1 (Plasma kallikrein)C1S (Complement component 1s subcomponent serine protease)KLK6 (Kallikrein-related peptidase 6)
Beyond the preview
Go deeper on recombinant C1 esterase inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant C1 esterase inhibitor.